Verrica Pharmaceuticals Inc. · NASDAQ:VRCA
Verrica Pharmaceuticals — Technical Presentation (June 2019)
13 slides from Verrica Pharmaceuticals's technical presentation, Jun 27, 2019
Slide 1: Topline Results from COVE-1: Phase 2 Clinical Trial of VP-102 in Common Warts
June 27, 2019 Topline Results from COVE-1: Phase 2 Clinical Trial of VP-102 in Patients with Common Warts Copyright © 2019 Verrica Pharmaceuticals. All rights reserved. Exhibit 99.2
Slide 2: Forward-looking statements and third-party data
Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Verrica’s own internal estimates and research. While Verrica believes these third-party
Slide 3: Verruca Vulgaris (Common Warts) Etiology and Clinical Presentation Overview
VERRUCA VULGARIS (COMMON WARTS) ETIOLOGY AND CLINICAL PRESENTATION OVERVIEW Caused by human papilloma virus (HPV) Infects patients of all ages Persistent infection, highly refractory Typically 2-5 lesions No FDA approved drug for the treatment of common warts Transmission Skin to skin contact Touchi
Slide 4: Cantharidin Has a Proven Dual Mechanism of Action
CANTHARIDIN HAS A PROVEN DUAL MECHANISM OF ACTION Targeted Destruction of Infected Skin Leads to Lesion Clearance Once applied, cantharidin activates neutral serine proteases that cause degeneration of the desmosomal plaque, leading to detachment of tonofilaments from desmosomes.(1) This leads to in
Slide 5: Successfully Completed a Phase 2 Study (COVE-1) in Common Warts
WE HAVE successfully COMPLETED A PHASE 2 STUDY (COVE-1) IN common WARTS Study Design Cohort 1: one center Cohort 2: four centers Efficacy, safety & tolerability Endpoints Primary Percent of subjects with complete clearance of all treatable warts (baseline and new) at Day 84 Secondary Percent of subj
Slide 6: Demographics in COVE-1 Study
VP-102 (N=21) VP-102 (N=35) Randomized 21 35 Age (years) Mean 38 38 Median 37 42 Min, Max 7, 83 12, 67 Gender Female 11 (52.4%) 22 (62.9%) Male 10 (47.6%) 13 (37.1%) Discontinued 4 (19.0%) 2 (5.7%) Lost to follow-up 2 (9.5%) 1 (2.9%) Withdrawal by subject 2 (9.5%) 0 Protocol violation 0 1 (2.9%) Dem
Slide 7: Wart History for Subjects in COVE-1 Study
VP-102 (N=35) Time Since Clinical Diagnosis (months) Mean 15.9 Age at Diagnosis Mean 36.4 Any Previous Treatment for Common Warts? Yes 24 (68.6%) Wart number at Baseline Mean 1.65 VP-102 (N=21) Time Since Clinical Diagnosis (months) Mean 70.3 Age at Diagnosis Mean 32.1 Any Previous Treatment for Com
Slide 8: VP-102 Demonstrated Clinically Meaningful Efficacy on Primary Endpoint of Complete Clearance
VP-102 demonstrated Clinically meaningful efficacy on Primary endpoint of complete CLEARANCE in COVE-1 STUDY Percentage of Subjects with Complete Clearance COHORT 1 Weeks1 44% 35% 20% 2% Wart count: % Change from Baseline Percentage of Subjects with Complete Clearance COHORT 2 Weeks 51% 31% 29% 24%
Slide 9: Safety Summary for COVE-1 Study
Subjects with at least one… VP-102 (N=21) n (%) TEAE (Treatment Emergent AE) 20 (95.2) Mild TEAE 20 (95.2) Moderate TEAE 9 (42.9) Severe TEAE 2 (9.5) TEAE related to drug 20 (95.2) Serious TEAE 0 (0) TEAE leading to discontinuation 0 (0) Local Skin Reaction TEAE 20 (95.2) TEAE of Papilloma Viral Inf
Slide 10: Adverse Events in COVE-1 Study
adverse events in cove-1 study Cohort 1 (N= 21) n (%) Cohort 2 (N=34) n (%) PREFERRED TERM NAME Application site vesicles 20 (95.2) 27 (79.4) Application site pain 20 (95.2) 26 (76.5) Application site erythema 13 (61.9) 19 (55.9) Application site pruritus 9 (42.9) 16 (47.1) Application site scab 8 (
Slide 11: Realizing the Common Warts Opportunity
Realizing the common warts Opportunity Nguyen et al, Laser Treatment of Nongenital Verrucae A Systemic Review. JAMA Dermatology. 2016; 152(9): 1025-1033 IQVIA Anonymous Longitudinal Patient Level Data (APLD) for 12 months ending September 2018 Prevalence in U.S. US Prevalence of ~22 million in commo
Slide 12: Significant Recent and Expected Clinical Milestones
DATE EVENT 1Q 2018 Received go ahead from FDA to initiate two Phase 3 trials in molluscum, including SPA on pivotal trial 1Q 2018 Initiated Phase 3 trials for molluscum and Phase 2 trial for common warts 3Q 2018 Completed enrollment in two pivotal Phase 3 trials in molluscum 1Q 2019 Positive topline
Slide 13: Summary & Path Forward
VP-102 exhibited a clinically meaningful proportion of subjects demonstrating complete clearance of all treatable warts with a treatment regimen of up to 4 applications administered every 21 days VP-102 was well-tolerated, with no serious adverse events reported No FDA approved treatments are curren
Verrica Pharmaceuticals — Technical Presentation (June 2019) on 6ix